drugset / Trial / NCT00447551

Canadian Aesthetic Experience With Sculptra Therapy

NCT00447551 ↗

Phase 4 Completed 76 enrolled Bausch Health Americas, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Primary objective To evaluate the degree of correction achievable with Sculptra for nasolabial folds, mid- and lower facial volume loss, jawline laxity and other signs of facial ageing. To document the types and incidence of device-related adverse events with Sculptra.

Timeline

Start
2007-01
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Poly-L-Lactic Acid Small molecule — Other

Indications